Table 1.

Selected Demographic and Clinical Characteristics of the Study Cohort and Subjects with and without De Novo Malignancy

	All LT Recipients N=534	Patients with de novo malignancy N= 73	Patients without de novo malignancy N=461	P value
Mean age at LT (years, ± sd)	49.5 ± 14	53 ± 12	49 ± 14	0.01
Age≥18years	94%	97%	94%	0.2
Age≥60years	19%	25%	18%	0.2
Male gender	65%	67%	65%	0.7
Race
Caucasian	86%	81%	87%
Black	6%	11%	5%	0.09
Hispanic	2%	None	3%
Other	6%	8%	5%
Personal history of cancer	12%	17%	11%	0.14
Liver cancer	9%	11%	9%	0.5
Family history of cancer	15%	22%	14%	0.07
History of tobacco use	36%	45%	34%	0.07
History of alcohol use	34%	34%	34%	0.9
History of diabetes mellitus	32%	37%	32%	0.4
Etiology of liver disease
Alcohol	23%	25%	23%	0.8
Viral	46%	49%	45%	0.5
NASH	11%	12%	10%	0.6
Autoimmune	14%	11%	15%	0.4
Immunosuppression
Primary agent
Tacrolimus	84%	85%	84%	0.6
Cyclosporin	13%	14%	12%	0.6
Sirolimus	3%	1%	3%	0.4
Multiple agents used (Primary   agent with azathioprine/   mycophenolate mofetil and/or   prednisone)	30%	30%	30%	0.7
Follow up (years, mean ± s.d.)	5.7 ± 3.2	6.1 ± 2.6	5.6 ± 3.3	0.15

LT: Liver transplantation, NASH: Nonalcoholic steatohepatitis;